Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

Isabel Tundidor, Marta Seijo-Vila, Sandra Blasco-Benito, María Rubert-Hernández, Sandra Adámez, Clara Andradas, Sara Manzano, Isabel Álvarez-López, Cristina Sarasqueta, María Villa-Morales, Carmen González-Lois, Esther Ramírez-Medina, Belén Almoguera, Antonio J. Sánchez-López, Laura Bindila, Sigrid Hamann, Norbert Arnold, Christoph Röcken, Ignacio Heras-Murillo, David Sancho, Gema Moreno-Bueno, María M. Caffarel, Manuel Guzmán, Cristina Sánchez () and Eduardo Pérez-Gómez ()
Additional contact information
Isabel Tundidor: Complutense University
Marta Seijo-Vila: Complutense University
Sandra Blasco-Benito: Complutense University
María Rubert-Hernández: Complutense University
Sandra Adámez: Complutense University
Clara Andradas: Telethon Kids Institute
Sara Manzano: Biodonostia Health Research Institute
Isabel Álvarez-López: Biodonostia Health Research Institute
Cristina Sarasqueta: Biodonostia Health Research Institute
María Villa-Morales: Centro de Biología Molecular Severo Ochoa (CBMSO) (CSIC-UAM)
Carmen González-Lois: Hospital Universitario Puerta de Hierro, Majadahonda
Esther Ramírez-Medina: Hospital Universitario Puerta de Hierro, Majadahonda
Belén Almoguera: Hospital Universitario Puerta de Hierro, Majadahonda
Antonio J. Sánchez-López: Biobank Hospital Universitario Puerta de Hierro Majadahonda
Laura Bindila: University Medical Center
Sigrid Hamann: University Hospital Schleswig-Holstein
Norbert Arnold: University Hospital Schleswig-Holstein
Christoph Röcken: University Hospital Schleswig-Holstein
Ignacio Heras-Murillo: Centro Nacional de Investigaciones Cardiovasculares (CNIC)
David Sancho: Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Gema Moreno-Bueno: Autonomous University of Madrid; Instituto de Investigación Hospital Universitario La Paz (IdiPaz); Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
María M. Caffarel: Biodonostia Health Research Institute
Manuel Guzmán: Complutense University
Cristina Sánchez: Complutense University
Eduardo Pérez-Gómez: Complutense University

Nature Communications, 2023, vol. 14, issue 1, 1-15

Abstract: Abstract Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-38750-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-38750-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-38750-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().